|
|
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Sotalol#Adult Indications and Dosage]] |
| {{Sotalol}}
| |
| {{CMG}}
| |
| | |
| ==Indications and Usage==
| |
| | |
| ====1.1 Substitution for Oral Sotalol Therapy====
| |
| | |
| Intravenous sotalol can substitute for oral sotalol in patients who are unable to take sotalol orally.
| |
| | |
| ====1.2 Delay in Recurrence of Atrial Fibrillation/Atrial Flutter====
| |
| | |
| Sotalol is indicated for the maintenance of normal sinus rhythm [delay in time to recurrence of atrial fibrillation/atrial flutter (AFIB/AFL)] in patients with symptomatic AFIB/AFL who are currently in sinus rhythm. Because sotalol can cause life-threatening ventricular arrhythmias, it should be reserved for patients in whom AFIB/AFL is highly symptomatic. Patients with paroxysmal AFIB whose AFIB/AFL is easily reversed (by Valsalva maneuver, for example) should usually not be given sotalol. In general, antiarrhythmic therapy for AFIB/AFL aims to prolong the time in normal sinus rhythm. Recurrence is expected in some patients [see Clinical Studies (14.2)].
| |
| | |
| Patients with atrial fibrillation should be anticoagulated according to usual medical practice.
| |
| | |
| ====1.3 Documented Life-Threatening Ventricular Arrhythmia====
| |
| | |
| Sotalol is indicated for the treatment of documented life-threatening ventricular arrhythmias. Because of the proarrhythmic effects of sotalol[see Warnings and Precautions (5.1)] including a 1.5 to 2% rate of Torsade de Pointes or new VT/VF in patients with either NSVT or supraventricular arrhythmias, its use in patients with less severe arrhythmias, even if the patients are symptomatic, is generally not recommended. Treatment of patients with asymptomatic ventricular premature contractions should be avoided. In life-threatening ventricular arrhythmias, the response to treatment should then be evaluated by a suitable method (e.g., PES or Holter monitoring) at steady state blood levels of drug prior to continuing the patient on chronic therapy. Antiarrhythmic drugs may not enhance survival in patients with ventricular arrhythmias.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = SOTALOL HYDROCHLORIDE INJECTION [BIONICHE PHARMA USA LLC] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2afe7385-2441-4e22-b63e-ab8614b275df | publisher = | date = | accessdate = }}</ref> | |
| | |
| ==References==
| |
| {{Reflist}}
| |
| | |
| {{FDA}}
| |
| | |
| [[Category:Antiarrhythmic agents]]
| |
| [[Category:Beta blockers]]
| |
| [[Category:Drugs]]
| |